Without a Ribbon
  • About
    • Events
    • Get In Touch
  • Rare Cancer Resources
  • Shop
  • How You Can Help
  • Meet Warriors
  • News
  • Login
  • Register

Select Page

HELP

LEARN

EVENTS

Our New Resource Page for Neuroendocrine Tumour of the Lung

Become part of our growing rare cancer community.
Join our Facebook support group

Join Now

Posted by fatima.shakeel@opmc.co | May 29, 2025

Neuroendocrine tumour of The Lung (Lung NETs) are a rare and unusual form of lung cancer that originates in neuroendocrine cells—specialised lung cells that help regulate key body functions by releasing hormones. These tumours can vary significantly in behaviour. Some grow slowly and are considered less harmful, while others are aggressive and cancerous.

Many sufferers of Neuroendocrine tumour of The Lung struggle because they feel that their disease doesn’t have the same level of awareness as more common cancers. Without a Ribbon is an Australian non-profit organisation that believes that rare cancers should never go unnoticed. We aim to provide a detailed set of resources and information for anyone suffering from cancers such as Neuroendocrine tumour of The Lung. We have recently created an Neuroendocrine tumour of The Lung resource page to help sufferers understand their disease. It covers the symptoms, available treatments and other important information.

We hope that this resource page will help you or a friend/family member to learn about their illness and aid them through their battle with the disease.

If you want to help make a difference for sufferers of Neuroendocrine tumour of The Lung, click here to learn how you can help!

Click the link below to read our resource page on Neuroendocrine tumour of The Lung:

 

View Neuroendocrine tumour of The Lung Resource Page

Share:

PreviousNeuroendocrine Tumour of the Lung (Lung NET)
NextMastocytosis – A Rare Immune System Disorder

If you need any help or advice just

Get In Touch

© Without a Ribbon 2019. All rights reserved.Powered by WEB 105 Creative

Stay up to date.

Sign up to our newsletter